ClinicalTrials.gg
CompletedNCT02966483Updated Oct 16, 2026

Transanal Versus Laparoscopic Total Mesorectal Excision For Rectal Cancer

An interventional study of TaTME and LpTME in Rectal Neoplasms Malignant and Surgery, sponsored by Sun Yat-sen University. Completed at 16 sites in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-10-16.

Sponsored by Sun Yat-sen University · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Registered 7 months after the study started (first participant enrolled Apr 2016, registered Nov 2016).
Updated Oct 16, 2026Now CompletedPrimary completion moved+4 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
1,115
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 39 studies in Rectal Neoplasms by Sun Yat-sen University — 19 open to participants now, 24 under way, 6 of them phase 3. Rectal Neoplasms · Sun Yat-sen University.

Enrollment
2nd of 31
1,115 · median 100
Started
2016
with 2 others
No phase
8 of 39
5 open now
Registered
9th of 39
by date

Among the 39 studies in Rectal Neoplasms by Sun Yat-sen University, this one is the 2nd largest by enrollment of the 31 interventional ones that give a count, is one of 3 that started in 2016, is one of 8 with no phase, and was the 9th registered.

Rectal Neoplasms

2,404 studies on the registry are indexed under Rectal Neoplasms; 588 are open to participants now.

Browse Rectal Neoplasms studies →

Open to participants now

19 of the 39 studies in Rectal Neoplasms by Sun Yat-sen University are open now, in 1 country. Recruiting first, the newest first:

14 more — sign in →

By country, each count listing its studies:

All 19 open studies →

Where they have run

Who these studies take

Of the 404 Rectal Neoplasms studies recruiting now, 209 (52%) set no upper age limit and 143 (35%) stop at 75 or younger; 19 take children under 18; 16 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 39 studies in Rectal Neoplasms by Sun Yat-sen University, or all of them as a file.
02

Study summary

Laparoscopic surgery for rectal cancer has been successfully proven to be a non-inferior alternative regarding resection quality, and oncological outcomes of patients as compared to open surgery in mangy clinical trails. Moreover, laparoscopic surgery is advantageous over open surgery with regard to operative invasiveness, patient's recovery, and wound related complications. Thus, laparoscopic surgery has gained great popularity over the past decades. However, specifically for mid and low rectal cancer, laparoscopic surgery is technically demanding, which sometimes leads to high morbidity and unsatisfactory resection quality, especially in challenging cases such as bulky mesorectum, enlarged prostate, irradiated pelvis, etc. Under this circumstance, transanal total mesorectal excision (TaTME) , the so called "down-to-up" alternative, has emerged as a promising solution to these problems in recent years and more and more small studies have proven the feasibility and advantages of this technique, making it become a hot topic among both literature and conferences. However, TaTME is still at early birth, higher-level evidences, either multicentric, or comparative study with conventional surgery is strikingly lacking. Thus the investigators conduct this multicentre randomised clinical trial, comparing transanal TME versus laparoscopic TME for mid and low rectal cancer, aiming to prove the hypothesis that TaTME may achieve better resection quality and result in non-inferior oncological outcome, as well as short term operative morbidity and mortality.

Read the detailed description

Background:In recent years, transanal mesorectal excision (TaTME) has emerged as a promising surgical alternative for rectal cancer, especially for mid and low rectal cancer. Theoretically, TaTME holds the potential advantage of providing better access to mobilize the distal rectum, and thus could achieve better pathologic outcomes, such as lower involved circumferential margin (CRM) and incomplete resected mesorectum, which could translate into better oncological outcome for the patients in the long term. However, until now, the feasibility and the non-inferiority (compared with laparoscopic total mesorectal excision, LpTME) of this technique has only been validated in studies with limitations of small sample size, retrospective nature.

Study Objective:This study aims to evaluate the TaTME technique compared with conventional laparoscopic rectal surgery, focusing on resection quality, as well as long-term survival results.

Study design This study is a prospective, multi-center, randomized, open-label, parallel group trial. The randomisation ratio of TaTME over LpTME will be 1:1. A central electronic data capture (EDC) system will be utilized for randomization, electronic CRF and data collection. All comparative analyses will be conducted on an "intention to treat" basis.

Sample size: Sample-size calculation of this trial based on 3-year DFS and 5-year OS; but the sample size according to 5-year OS was larger than that based on 3-year DFS. The expected 5-year OS among clinical stage I-III rectal cancer patients treated with laTME was 77·4%. Allowing a difference of 10% as the non-inferiority margin, 910 patients would be required to sufficiently declare taTME noninferior to laTME in 5-year OS based on a log-rank test with an α error of 2·5% (in a two-sided test) and power of 80%. Assuming a dropout rate of 20%, a total of 1114 patients were planned to enroll for this trial.

Study Endpoints:The primary end point of this study is 3-year disease-free survival (DFS) rate and a 5-year overall survival (OS) rate. Secondary endpoints include: 1) resection quality, mainly including circumferential involvement rate, and completeness of mesorectum. Resected specimen was pathologically processed and assessed at each center by trained and qualified pathologists independently.2)short term operative results such as morbidity and mortality, etc.; 3) long term oncological outcome such as local recurrence, and overall survival. Besides, functional outcome and quality of life are also evaluated.

03

Conditions studied

  • Rectal Neoplasms Malignant
  • Surgery

Browse trials for

Keywords

  • Rectal cancer
  • Laparoscopic surgery
  • Total mesorectal excision
  • Transanal
  • Multicentre randomised clinical trial
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

proven rectal adenocarcinoma;

tumor located below the level of peritoneal reflection ;

diagnosis of rectal cancer amenable to curative surgery;

no evidence of distant ;

preoperative tumor stage within III;

no threaten mesorectal fascia (MRF)after therapy;

no to laparoscopic surgery;

without history of other ;

Written

Exclusion criteria

Exclusion Criteria:

could not perform sphincter preservation surgery (requiring a Mile's procedure);

T4b tumor invading adjacent organs;

T1 tumors that can be locally resected

should take therapy but refuse it;

recurrent cancer;

concurrent or previous diagnosis of invasive cancer within 5 years;

emergent surgery with intestinal obstruction or perforation;

history of colorectal surgery;

fecal incontinence;

history of inflammatory bowel disease;

with to general anaesthesia( 4 or 5);

pregnant or breast-feeding;

history of mental disorder

Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ASA physical status

The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
1,115 participants (actual)

Study arms

  • Experimental
    Transanal Total Mesorectal Excision

    The rectum is mobilized and resected transanally (from bottom to up) according to TME principles, via transanal platform (either rigid or flexible platform).An ideal TaTME is defined as the extraperitoneal portion of the rectum being mobilized from below.

    Procedure: TaTME

  • Active comparator
    Laparoscopic Total Mesorectal Excision

    The traditional laparoscopic TME (LpTME) was performed via standard laparoscopic techniques, including multiple trocars and conventional laparoscopic instruments.

    Procedure: LpTME

Interventions

  • ProcedureTaTME

    Transanal Total Mesorectal Excision

    Also known as: Transanal TME

  • ProcedureLpTME

    Conventional Laparoscopic Total Mesorectal Excision

    Also known as: Laparoscopic TME

06

What researchers measure

Primary outcomes

  1. Disease-free survival

    Disease-free survival

    Time frame: 3 years

  2. Overall survival

    Overall survival

    Time frame: 5 years

Secondary outcomes

  1. Positive circumferential resection margin (CRM)

    Involved CRM (tumor cells \<1mm)

    Time frame: 3 years

  2. Overall survival

    Overall survival

    Time frame: 10 years

  3. Mesorectal completeness

    The quality of the mesorectum or TME specimen (complete;nearly complete; incomplete)

    Time frame: 3 years

  4. Number of retrieved lymph nodes

    Number of retrieved lymph nodes

    Time frame: 3 years

  5. Morbidity rate

    Morbidity rate

    Time frame: 1 years

  6. Mortality rate

    Mortality rate

    Time frame: 1 years

  7. Anorectal function outcomes

    To evaluate defecating function with Wexner score

    Time frame: 3 years

  8. Sexual functional outcomes

    To evaluate sexual function with IIEF(International Index of Erectile Function) questionnaire

    Time frame: 3 years

  9. The patient's Quality of life: EORTC QLQ-30 questionnaire

    To evaluate quality of life with EORTC QLQ-30 questionnaire

    Time frame: 3 years

07

Study locations

16 sites
  • Department of General Surgery, Peking Union Medical College Hospital, Peking Union Medical College and Chinese Academy of Medical Sciences
    Beijing, Beijing Municipality 100730, China
  • Department of General Surgery, Daping Hospital, Army Medical university
    Chongqing, Chongqing Municipality 400042, China
  • Department of colorectal surgery, the Sixth Affiliated Hospital, Sun Yat-Sen University
    Guangzhou, Guangdong 510000, China
  • Nanfang Hospital
    Guangzhou, Guangdong 510559, China
  • The Affiliated Hospital of Guangdong Medical University
    Zhanjiang, Guangdong 524001, China
  • Affiliated Hospital of Zunyi Medical University
    Zunyi, Guizhou 563003, China
  • The Third Xiangya Hospital of Central South University
    Changsha, Hunan 410013, China
  • The First Affiliated Hospital of University of South China
    Hengyang, Hunan 421001, China
  • Department of Gastrointestinal Surgery, The First Hospital of Jilin University
    Changchun, Jilin 130021, China
  • Department of Colorectal Surgery, Shengjing Hospital of China Medical University
    Shenyang, Liaoning 110004, China
  • The First Affiliated Hospital of Xi'an Jiaotong University
    Xi'an, Shaanxi 710061, China
  • Ruijin Hospital, Shanghai Jiao Tong University School of Medicine
    Shanghai, Shanghai Municipality 200025, China
  • Department of Gastrointestinal Surgery, Renji Hospital, School of Medicine, Shanghai Jiao Tong University,
    Shanghai, Shanghai Municipality 200127, China
  • Department of Gastrointestinal Surgery,The Affiliated Nanchong Central Hospital of North Sichuan Medical College
    Nanchong, Sichuan 637000, China
  • Department of gastrointestinal surgery, the Second People's Hospital of Yibin
    Yibin, Sichuan 644000, China
  • XinQiao Hospital of Army Medical University
    Chongqing, 400037, China
08

References and documents

Publications

  • Chen WH, Kang L, Luo SL, Zhang XW, Huang Y, Liu ZH, Wang JP. Transanal total mesorectal excision assisted by single-port laparoscopic surgery for low rectal cancer. Tech Coloproctol. 2015 Sep;19(9):527-34. doi: 10.1007/s10151-015-1342-1. Epub 2015 Jul 29. PubMed 26220109 ↗
  • Kang L, Chen WH, Luo SL, Luo YX, Liu ZH, Huang MJ, Wang JP. Transanal total mesorectal excision for rectal cancer: a preliminary report. Surg Endosc. 2016 Jun;30(6):2552-62. doi: 10.1007/s00464-015-4521-2. Epub 2015 Aug 27. PubMed 26310534 ↗
  • Zeng Z, Luo S, Zhang H, Wu M, Ma D, Wang Q, Xie M, Xu Q, Ouyang J, Xiao Y, Song Y, Feng B, Xu Q, Wang Y, Zhang Y, Shi L, Ling L, Zhang X, Huang L, Yang Z, Peng J, Wu X, Ren D, Huang M, Lan P, Wang J, Tong W, Ren M, Liu H, Kang L; Chinese Transanal Endoscopic Surgery Collaborative (CTESC) Group. Transanal vs Laparoscopic Total Mesorectal Excision and 3-Year Disease-Free Survival in Rectal Cancer: The TaLaR Randomized Clinical Trial. JAMA. 2025 Mar 4;333(9):774-783. doi: 10.1001/jama.2024.24276. PubMed 39847361 ↗
  • Chen M, Ye F, Huang P, Liang Z, Liu H, Zheng X, Li W, Luo S, Kang L, Huang L. Inflammatory stress response after transanal vs laparoscopic total mesorectal excision: a cohort study based on the TaLaR trial. Int J Surg. 2024 Jan 1;110(1):151-158. doi: 10.1097/JS9.0000000000000838. PubMed 37916926 ↗
  • Zeng Z, Luo S, Chen J, Cai Y, Zhang X, Kang L. Comparison of pathological outcomes after transanal versus laparoscopic total mesorectal excision: a prospective study using data from randomized control trial. Surg Endosc. 2020 Sep;34(9):3956-3962. doi: 10.1007/s00464-019-07167-1. Epub 2019 Oct 4. PubMed 31586244 ↗

Individual participant data

Plan to share: Undecided

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2016 to primary completion in Sep 2026, 125 months.

Of 329 non-industry interventional studies with no phase under Rectal Neoplasms, half reached primary completion within 51 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 78. This study's 125 months is above that.

Counting every sponsor, half of 336 studies reached it within 51 months; a quarter within 23 and three quarters within 78.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 16, 2026: primary completion Jul 2026 → Sep 2026 and completion Jul 2026 → Sep 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Nov 8, 2016
First posted
Nov 17, 2016
StartActual
Apr 2016
Primary completionActual
Sep 2026was Jul 2026
CompletionActual
Sep 2026was Jul 2026
Last update
Oct 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Completed
changed Oct 16, 2026
Sites
4 sites added, 4 sites removed
Show 4 added (4 China)
  • Department of General Surgery, Peking Union Medical College Hospital, Peking Union Medical College and Chinese Academy of Medical Sciences · Beijing, China
  • Department of General Surgery, Daping Hospital, Army Medical university · Chongqing, China
  • Ruijin Hospital, Shanghai Jiao Tong University School of Medicine · Shanghai, China
  • Department of Gastrointestinal Surgery, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, · Shanghai, China
Show 4 removed
  • Department of General Surgery, Peking Union Medical College Hospital, Peking Union Medical College and Chinese Academy of Medical Sciences · Beijing, China
  • Department of General Surgery, Daping Hospital, Army Medical university · Chongqing, China
  • Ruijin Hospital, Shanghai Jiao Tong University School of Medicine · Shanghai, China
  • Department of Gastrointestinal Surgery, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, · Shanghai, China
Oct 16, 2026
Primary completion
Jul 2026→Sep 2026 (actual)
Oct 16, 2026
Study completion
Jul 2026→Sep 2026 (actual)
Oct 16, 2026
Enrollment
1114 (estimated)→1115 (actual)
Oct 16, 2026
Publications
2 publications citing this study linked from PubMed, e.g. PubMed 39847361 ↗
Oct 16, 2026
Show all 1 update
  1. Oct 16, 2026
    Recruiting→Completed
    Publications 2 publications citing this study linked from PubMed, e.g. PubMed 39847361 ↗
    4 sites added, 4 sites removed
    Show 4 added (4 China)
    • Department of General Surgery, Peking Union Medical College Hospital, Peking Union Medical College and Chinese Academy of Medical Sciences · Beijing, China
    • Department of General Surgery, Daping Hospital, Army Medical university · Chongqing, China
    • Ruijin Hospital, Shanghai Jiao Tong University School of Medicine · Shanghai, China
    • Department of Gastrointestinal Surgery, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, · Shanghai, China
    Show 4 removed
    • Department of General Surgery, Peking Union Medical College Hospital, Peking Union Medical College and Chinese Academy of Medical Sciences · Beijing, China
    • Department of General Surgery, Daping Hospital, Army Medical university · Chongqing, China
    • Ruijin Hospital, Shanghai Jiao Tong University School of Medicine · Shanghai, China
    • Department of Gastrointestinal Surgery, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, · Shanghai, China
    Primary completion Jul 2026→Sep 2026 (now actual)
    Study completion Jul 2026→Sep 2026 (now actual)
    Enrollment 1114 (estimated)→1115 (actual)
    + 5 other changes: index terms, identifiers, verification date, oversight details and contact details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT02966483
Collaborators
Peking Union Medical College Hospital, The First Hospital of Jilin University, RenJi Hospital, Shengjing Hospital, The Second People's Hospital of Yibin, Daping Hospital and the Research Institute of Surgery of the Third Military Medical University, Nanchong Central Hospital, Zunyi Medical College, The First Affiliated Hospital of University of South China, Xinqiao Hospital, Nanfang Hospital, Southern Medical University, First Affiliated Hospital Xi'an Jiaotong University, Ruijin Hospital, Affiliated Hospital of Guangdong Medical University, The Third Xiangya Hospital of Central South University
Responsible party
Yanhong Deng (MD, Sun Yat-sen University) — Principal investigator
First posted
Nov 17, 2016
Start date
Apr 2016
Primary completion
Sep 2026
Completion
Sep 2026
Last update
Oct 16, 2026

Study contacts

Jianping Wang, MD,PHD
principal investigator · Sixth Affiliated Hospital, Sun Yat-sen University

Oversight

FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion